Results 211 to 220 of about 203,270 (263)

Efficacy of a Tumor Necrosis Factor Inhibitor in Chronic Low‐Back Pain With Modic Type 1 Changes: A Randomized Controlled Trial

Arthritis &Rheumatology, EarlyView.
Efficacy of a Tumor necrosis inhibitor in chronic low‐back pain with Modic type 1 changes: The BackToBasic study, A randomized controlled trial. Objective The efficacy of tumor necrosis factor inhibitors for treating chronic low‐back pain with Modic changes is uncertain.
Elisabeth Gjefsen, Lars C. Bråten, Erica Ponzi, Magnhild H. Dagestad, Gunn H. Marchand, Thomas Kadar, Gunnstein Bakland, Anne J. Haugen, Fredrik Granviken, Tonje W. Flørenes, Nils Vetti, Lars Grøvle, Aksel T. Nilsen, Astrid Lunestad, Thor E. Holmgard, Morten Valberg, Nils Bolstad, Ansgar Espeland, Jens I. Brox, Guro L. Goll, Kjersti Storheim, John‐Anker Zwart   +21 more
wiley   +1 more source

Atherosclerotic Plaque Progression and Incident Cardiovascular Events in a 10‐Year Prospective Study of Patients With Systemic Lupus Erythematosus: The Impact of Persistent Cardiovascular Risk Factor Target Attainment and Sustained DORIS Remission

Arthritis &Rheumatology, EarlyView.
Objective Cardiovascular disease (CVD) is a leading cause of death in individuals with systemic lupus erythematosus (SLE). We assessed atherosclerotic plaque progression and incident cardiovascular events in patients with SLE over a 10‐year follow‐up.
Nikolaos Papazoglou, Petros P. Sfikakis, Maria G. Tektonidou   +2 more
wiley   +1 more source

Clinical factors associated with pneumocystis pneumonia despite its primary prophylaxis: When to stop prophylaxis?

Arthritis &Rheumatology, Accepted Article.
Objective Although previous studies show that primary prophylaxis against Pneumocystis jirovecii pneumonia (PJP) is effective in patients with rheumatic diseases receiving immunosuppressive treatment, there is limited evidence regarding the optimal timing for prophylaxis withdrawal.
Ju Yeon Kim, Se Rim Choi, Jin Kyun Park, Eun Young Lee, Eun Bong Lee, Jun Won Park   +5 more
wiley   +1 more source

Adverse events associated with monoclonal antibodies used for treatment of COVID‐19: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims This review aimed to synthesise the evidence related to the incidence of serious and non‐serious adverse events with the use of monoclonal antibodies (mAbs) among COVID‐19 patients. Methods Databases were searched from January 2020 to September 2023 for randomized clinical trials (RCTs) that used mAbs for the treatment of COVID‐19 regardless of ...
Htet Htet, Han You Kyung, Ismail Abdul Sattar Burud, Heethal Jaiprakash, Thiruselvi Subramaniam, Igor Iezhitsa, Renu Agarwal   +6 more
wiley   +1 more source

Severe myelosuppression and alopecia after thiopurine initiation in a patient with NUDT15 deficiency

British Journal of Clinical Pharmacology, EarlyView.
Thiopurines are a class of immunosuppressant and antineoplastic agents. They are widely used in the treatment of inflammatory bowel disease, haematological malignancies and autoimmune diseases, but can cause significant toxicity. Inherited gene mutations are now recognized as independent risk factors for severe adverse drug reactions to thiopurines ...
Annie Siyu Wu, Lee Mozessohn, Richard B. Kim, Jonathan S. Zipursky   +3 more
wiley   +1 more source

The contribution of extracellular RNA and its derived biomaterials in disease management

BMEMat, EarlyView.
The implications of exRNA's biological function and the structural uniqueness of RNA help establish a close connection between RNA, material, and modern medicine. Abstract The RNA found in the circular system is known as extracellular RNA (exRNA). This kind of RNA has been found to play a biological role similar to that of a messenger. They can be used
Yu Wei, Zhangyi Wang, Zixuan Qin, Qianqian Wan, Yutao Li, Franklin R. Tay, Chenyu Wang, Tong Zhang, Lina Niu   +8 more
wiley   +1 more source

Liver organoids: From 3D printing to biomedical applications

BMEMat, EarlyView.
A comprehensive review on liver organoids culture techniques from 3D printing to organ‐on‐chip, as well as focusing on challenges and perspectives for advancement liver organoids in various future applications. Abstract The liver is an immune organ, especially an immune tolerance organ.
Ying Shi, Xin Han, Zheng Zhang, Jiangtao Xu, Guozhen Liu   +4 more
wiley   +1 more source

Unveiling the complexity of cellular senescence in cancers: From mechanism to therapeutic opportunities

BMEMat, EarlyView.
This review highlights the complex roles of cellular senescence in cancer progression and suppression, discusses the mechanisms and regulatory pathways involved, and evaluates the efficacy of the “One‐Two punch” sequential treatment approach while addressing emerging challenges in this novel therapeutic strategy.
Qiuming Pan, Ye Zhu, Zhi Ye, Huayang Zhang, Junxi Wang, Guozhong Yi, Zhiyong Li, Rongyang Xu, Luyao Wang, Zhenzhen Wu, Songtao Qi, Guanglong Huang, Shanqiang Qu   +12 more
wiley   +1 more source

Breaking barriers: Smart vaccine platforms for cancer immunomodulation

Cancer Communications, EarlyView.
Abstract Despite significant advancements in cancer treatment, current therapies often fail to completely eradicate malignant cells. This shortfall underscores the urgent need to explore alternative approaches such as cancer vaccines. Leveraging the immune system's natural ability to target and kill cancer cells holds great therapeutic potential ...
Mohammad Mahmoudi Gomari, Taha Ghantabpour, Nima Pourgholam, Neda Rostami, Stephen M. Hatfield, Farzaneh Namazifar, Shadi Abkhiz, Seyed Sadegh Eslami, Mahsa Ramezanpour, Mahsa Darestanifarahani, Igor Astsaturov, Sidi A. Bencherif    +11 more
wiley   +1 more source

Blocking ITGA5 potentiates the efficacy of anti‐PD‐1 therapy on glioblastoma by remodeling tumor‐associated macrophages

Cancer Communications, EarlyView.
Abstract Background Glioblastoma (GBM) is largely refractory to antibodies against programmed cell death 1 (anti‐PD‐1) therapy. Fully understanding the cellular heterogeneity and immune adaptations in response to anti‐PD‐1 therapy is necessary to design more effective immunotherapies for GBM.
Rongrong Zhao, Ziwen Pan, Jiawei Qiu, Boyan Li, Yanhua Qi, Zijie Gao, Wei Qiu, Weijie Tang, Xiaofan Guo, Lin Deng, Gang Li, Hao Xue   +11 more
wiley   +1 more source